Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives Average Recommendation of “Buy” from Analysts

Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) have been given an average recommendation of “Buy” by the seven ratings firms that are currently covering the company, Marketbeat.com reports. Seven analysts have rated the stock with a buy recommendation. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $32.86.

Several research analysts recently weighed in on CPRX shares. StockNews.com cut shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, January 11th. Bank of America restated a “buy” rating and set a $30.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Thursday, January 9th. Stephens initiated coverage on shares of Catalyst Pharmaceuticals in a research report on Monday, November 18th. They issued an “overweight” rating and a $35.00 target price for the company. Truist Financial raised their price target on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a “buy” rating in a research report on Monday, November 11th. Finally, HC Wainwright upped their price objective on Catalyst Pharmaceuticals from $30.00 to $35.00 and gave the stock a “buy” rating in a report on Friday, January 10th.

Insider Buying and Selling

In other Catalyst Pharmaceuticals news, insider Steve Miller sold 50,000 shares of the stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $21.93, for a total transaction of $1,096,500.00. Following the completion of the sale, the insider now owns 686,996 shares of the company’s stock, valued at $15,065,822.28. This represents a 6.78 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Molly Harper sold 17,500 shares of the business’s stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $22.00, for a total transaction of $385,000.00. The disclosure for this sale can be found here. Insiders have sold a total of 79,500 shares of company stock worth $1,754,140 in the last ninety days. 11.00% of the stock is owned by insiders.

Institutional Investors Weigh In On Catalyst Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of CPRX. GAMMA Investing LLC raised its holdings in shares of Catalyst Pharmaceuticals by 62.1% during the third quarter. GAMMA Investing LLC now owns 1,778 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 681 shares in the last quarter. nVerses Capital LLC bought a new position in Catalyst Pharmaceuticals in the 3rd quarter worth $50,000. Larson Financial Group LLC lifted its position in shares of Catalyst Pharmaceuticals by 27,218.2% in the 3rd quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company’s stock worth $60,000 after purchasing an additional 2,994 shares during the period. KBC Group NV boosted its stake in shares of Catalyst Pharmaceuticals by 48.8% during the 4th quarter. KBC Group NV now owns 4,699 shares of the biopharmaceutical company’s stock valued at $98,000 after purchasing an additional 1,542 shares in the last quarter. Finally, Thurston Springer Miller Herd & Titak Inc. purchased a new position in shares of Catalyst Pharmaceuticals during the fourth quarter valued at about $134,000. Hedge funds and other institutional investors own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Stock Up 0.2 %

Shares of NASDAQ CPRX opened at $22.55 on Friday. The stock’s 50-day simple moving average is $21.79 and its two-hundred day simple moving average is $20.49. Catalyst Pharmaceuticals has a twelve month low of $13.12 and a twelve month high of $24.27. The firm has a market capitalization of $2.69 billion, a P/E ratio of 19.11, a P/E/G ratio of 2.28 and a beta of 0.79.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.